MT has been established as a standard treatment for LVO stroke. The incidence of stroke increases with the age. However, it is still controversial if MT would benefit the stroke patients who are 80 years or older as they are often excluded in clinical trials. We presented our experience of MT on this patient population.

All MT cases between 2015-2017 in our institution were retrospectively reviewed. They were divided into two groups: elderly group (EG) (≥80 years old(yo)) and the adult group (AG) (<80 yo). Median age, NIHSS on admission (AD) and discharge (DC), mRS on DC, DC disposition, recanalization rate, and complication were reviewed. TICI score 2b or higher was good recanalization. Favorable outcome was mRS 0-2. Fish Exact test was used for statistical analysis.

EG had 15 patients while the AG had 101 patients (12.9%).This was similar to the MR CLEAN study which had 16.2% elderly patients. Median age in the EG was 85 yo vs 63 yo in the AG. There was no difference of AD NIHSS (median (IQR) 17 (11-19) in the EG vs 17 (13-21) in the AG).Median time from last known normal to groin puncture was 350 min in the EG and 310 min in the AG (p=0.67). Both had similar good recanalization rate (80% in the EG vs 77.2% in the AG), and similar favorable outcome (20% vs 27.7%, p =0.73). EG had no symptomatic hemorrhage or other complications, while AG had one hemorrhage. EG had lower percentage than AG for home or acute rehabilitation (33.3% vs 58.1%, p=0.097).

Our Institution experience showed MT was safe and effective for elderly stroke patients. Age alone should not exclude patients from thrombectomy.